Recently, LWBP's independently developed new hepatitis B drug LW231 was unveiled at the 11th China (Shanghai) International Technology Fair, attracting widespread attention.
About LW231
LW231 is the world's first (FIC) bi-functional innovative drug developed by LWBP that utilizes the cGAS/STING pathway for immune-based antiviral therapy of chronic hepatitis B and has entered clinical trials. Research into this mechanism and animal trials have demonstrated that LW231 can effectively inhibit viral replication while activating the innate immune response, thereby eliminating HBV-infected hepatocytes. After discontinuation of the drug, there is no rebound, and newly generated hepatocytes are healthy cells, suggesting that chronic hepatitis B has achieved complete cure.
About LWBP
Founded in 2012, LWBP is an innovative drug R&D company led by world-renowned chemical drug experts. The company is committed to independently developing world-leading innovative drugs with global intellectual property rights to meet unmet clinical needs. Focusing on the development and industrialization of innovative drugs in the fields of antiviral, tumour immunity and autoimmune diseases, the company has carried out a number of self-developed small molecule drugs (FIC, first in class), and a number of them have entered the clinical trial stage. The core products have reached the international leading level in terms of clinical evaluation indexes, and are expected to become a major breakthrough in the relevant fields（New Class, First-in-Class）.
About CSITF
CSITF brings together 900+ exhibitors in the event that links the three key players in technology trading: businesses, academics and government. Visit us in 2025 for innovative live demonstrations and interactive seminars looking into the future of our life.
With over 20,000 attendees targeted for 2025, it is a must-attend event for those involved in exploring, developing or monitoring the latest technology trends, from laboratory to factory.
Join us at CSITF to discover game-changing innovations and solutions transforming the future of technology trading.
